FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009184484> ?p ?o ?g. }

• W2009184484 endingPage "720" @default.
• W2009184484 startingPage "713" @default.
• W2009184484 abstract "To compare the tremorlytic properties of pramipexole, a non-ergoline dopamine agonist to those of placebo as add on medication in patients with Parkinson's disease.Eighty four patients with early or advanced Parkinson's disease and marked, drug resistant tremor under a stable and optimised antiparkinsonian medication were included in a double blind, randomised, placebo controlled, multicentre study and assigned to add on treatment (7 week dose titration interval, 4 week maintenance period) with either pramipexole (n=44) or placebo (n=40) as adjunct. The primary end point was the absolute change in tremor score, defined as the sum of tremor related items (16, 20, 21) of the unified Parkinson's disease rating scale (UPDRS) in on periods. Secondary end points included the percentage change in tremor score, the absolute and percentage changes in long term EMG tremor registration, and the change in tremor self rating scales. Safety and tolerability were assessed on the basis of adverse events, laboratory tests, ECG, and vital signs.Pramipexole was significantly superior to placebo with a difference between treatment groups in the mean absolute change in tremor score of -4.4 (95% confidence interval (95% CI) -6.2 to -2.5) (p<0.0001), corresponding to a difference in the mean percentage change of -34.7% in favour of pramipexole. The secondary end points were consistent with the significant change in tremor score and provided further evidence for the benefit of pramipexole compared with placebo. Long term EMG registration as an objective measure showed a difference in mean absolute change in tremor occurrence of -15.2% (95%CI -21.4 to -9.0) (p<0.0001), and a difference in the mean percentage change of -45.7% in favour of pramipexole. The treatment effects increased during dose titration and remained stable during the 4 week maintenance dose period until the end of the study. The average daily pramipexole dose during maintenance was 4.1 (SD 0.9) mg. Safety analysis showed an increased rate of fatigue, insomnia, nausea, abdominal pain, and headache under pramipexole, comparable with previous studies.Pramipexole proved to be an effective agent for patients with Parkinson's disease and drug resistant tremor." @default.
• W2009184484 created "2016-06-24" @default.
• W2009184484 creator A5004253128 @default.
• W2009184484 creator A5004272477 @default.
• W2009184484 creator A5027662020 @default.
• W2009184484 creator A5047942484 @default.
• W2009184484 creator A5061542163 @default.
• W2009184484 creator A5067744605 @default.
• W2009184484 creator A5087435176 @default.
• W2009184484 date "2002-06-01" @default.
• W2009184484 modified "2023-10-16" @default.
• W2009184484 title "Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study" @default.
• W2009184484 cites W1018360976 @default.
• W2009184484 cites W1968931714 @default.
• W2009184484 cites W2019061461 @default.
• W2009184484 cites W2024720833 @default.
• W2009184484 cites W2028094886 @default.
• W2009184484 cites W2033711355 @default.
• W2009184484 cites W2047602610 @default.
• W2009184484 cites W2048149415 @default.
• W2009184484 cites W2052211978 @default.
• W2009184484 cites W2062193095 @default.
• W2009184484 cites W2075385428 @default.
• W2009184484 cites W2078512647 @default.
• W2009184484 cites W2127563467 @default.
• W2009184484 cites W2132881915 @default.
• W2009184484 cites W2139071033 @default.
• W2009184484 cites W2142359920 @default.
• W2009184484 cites W2145073096 @default.
• W2009184484 cites W2158005416 @default.
• W2009184484 cites W2165370634 @default.
• W2009184484 cites W2254141218 @default.
• W2009184484 cites W2328435466 @default.
• W2009184484 cites W2412391474 @default.
• W2009184484 doi "https://doi.org/10.1136/jnnp.72.6.713" @default.
• W2009184484 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1737934" @default.
• W2009184484 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12023411" @default.
• W2009184484 hasPublicationYear "2002" @default.
• W2009184484 type Work @default.
• W2009184484 sameAs 2009184484 @default.
• W2009184484 citedByCount "143" @default.
• W2009184484 countsByYear W20091844842012 @default.
• W2009184484 countsByYear W20091844842013 @default.
• W2009184484 countsByYear W20091844842014 @default.
• W2009184484 countsByYear W20091844842015 @default.
• W2009184484 countsByYear W20091844842016 @default.
• W2009184484 countsByYear W20091844842017 @default.
• W2009184484 countsByYear W20091844842018 @default.
• W2009184484 countsByYear W20091844842019 @default.
• W2009184484 countsByYear W20091844842020 @default.
• W2009184484 countsByYear W20091844842021 @default.
• W2009184484 countsByYear W20091844842022 @default.
• W2009184484 countsByYear W20091844842023 @default.
• W2009184484 crossrefType "journal-article" @default.
• W2009184484 hasAuthorship W2009184484A5004253128 @default.
• W2009184484 hasAuthorship W2009184484A5004272477 @default.
• W2009184484 hasAuthorship W2009184484A5027662020 @default.
• W2009184484 hasAuthorship W2009184484A5047942484 @default.
• W2009184484 hasAuthorship W2009184484A5061542163 @default.
• W2009184484 hasAuthorship W2009184484A5067744605 @default.
• W2009184484 hasAuthorship W2009184484A5087435176 @default.
• W2009184484 hasBestOaLocation W20091844841 @default.
• W2009184484 hasConcept C126322002 @default.
• W2009184484 hasConcept C138496976 @default.
• W2009184484 hasConcept C142724271 @default.
• W2009184484 hasConcept C15744967 @default.
• W2009184484 hasConcept C197934379 @default.
• W2009184484 hasConcept C204787440 @default.
• W2009184484 hasConcept C27081682 @default.
• W2009184484 hasConcept C2778375690 @default.
• W2009184484 hasConcept C2779134260 @default.
• W2009184484 hasConcept C2779734285 @default.
• W2009184484 hasConcept C2779989193 @default.
• W2009184484 hasConcept C2780112193 @default.
• W2009184484 hasConcept C42219234 @default.
• W2009184484 hasConcept C44249647 @default.
• W2009184484 hasConcept C71924100 @default.
• W2009184484 hasConcept C83849319 @default.
• W2009184484 hasConcept C99508421 @default.
• W2009184484 hasConceptScore W2009184484C126322002 @default.
• W2009184484 hasConceptScore W2009184484C138496976 @default.
• W2009184484 hasConceptScore W2009184484C142724271 @default.
• W2009184484 hasConceptScore W2009184484C15744967 @default.
• W2009184484 hasConceptScore W2009184484C197934379 @default.
• W2009184484 hasConceptScore W2009184484C204787440 @default.
• W2009184484 hasConceptScore W2009184484C27081682 @default.
• W2009184484 hasConceptScore W2009184484C2778375690 @default.
• W2009184484 hasConceptScore W2009184484C2779134260 @default.
• W2009184484 hasConceptScore W2009184484C2779734285 @default.
• W2009184484 hasConceptScore W2009184484C2779989193 @default.
• W2009184484 hasConceptScore W2009184484C2780112193 @default.
• W2009184484 hasConceptScore W2009184484C42219234 @default.
• W2009184484 hasConceptScore W2009184484C44249647 @default.
• W2009184484 hasConceptScore W2009184484C71924100 @default.
• W2009184484 hasConceptScore W2009184484C83849319 @default.
• W2009184484 hasConceptScore W2009184484C99508421 @default.
• W2009184484 hasIssue "6" @default.
• W2009184484 hasLocation W20091844841 @default.

• next